[go: up one dir, main page]

BRPI0408767A - inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv - Google Patents

inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv

Info

Publication number
BRPI0408767A
BRPI0408767A BRPI0408767-4A BRPI0408767A BRPI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A BR PI0408767 A BRPI0408767 A BR PI0408767A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
reverse transcriptase
formula
compounds
Prior art date
Application number
BRPI0408767-4A
Other languages
English (en)
Inventor
James Patrick Dunn
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122016023941-1A priority Critical patent/BR122016023941B1/pt
Publication of BRPI0408767A publication Critical patent/BRPI0408767A/pt
Publication of BRPI0408767B1 publication Critical patent/BRPI0408767B1/pt
Publication of BRPI0408767B8 publication Critical patent/BRPI0408767B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

"INIBIDORES DA TRANSCRIPTASE REVERSA NãO-NUCLEOSìDEOS I PARA O TRATAMENTO DE DOENçAS MEDIADAS PELO HIV". A presente invenção refere-se a novos compostos heterocíclicos de fórmula (I), em que R¬ 1¬-R¬ 4¬, X¬ 1¬ e X¬ 2¬ são como definidos no sumário e sais e solvatos farmaceuticamente aceitáveis destes, métodos para inibir ou modular a transcriptase reversa do Vírus da Imunodeficiência Humana (HIV) com compostos de fórmula (I), composições farmacêuticas contendo a fórmula I misturadas com pelo menos um solvente, veículo ou excipiente e processos para se preparar os compostos de fórmula I. O compostos são úteis para o tratamento de distúrbios, em que o HIV e os vírus geneticamente relacionados estão envolvidos.
BRPI0408767A 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica BRPI0408767B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45713003P 2003-03-24 2003-03-24
US60/457,130 2003-03-24
PCT/EP2004/002995 WO2004085411A1 (en) 2003-03-24 2004-03-22 Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases

Publications (3)

Publication Number Publication Date
BRPI0408767A true BRPI0408767A (pt) 2006-03-28
BRPI0408767B1 BRPI0408767B1 (pt) 2017-10-31
BRPI0408767B8 BRPI0408767B8 (pt) 2021-05-25

Family

ID=33098199

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0408767A BRPI0408767B8 (pt) 2003-03-24 2004-03-22 inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122016023941-1A BR122016023941B1 (pt) 2003-03-24 2004-03-22 Inibidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso e composição farmacêutica

Country Status (20)

Country Link
US (2) US7208509B2 (pt)
EP (1) EP1608633B1 (pt)
JP (1) JP4708329B2 (pt)
KR (1) KR101122456B1 (pt)
CN (1) CN100588650C (pt)
AR (1) AR043673A1 (pt)
AU (1) AU2004224153B2 (pt)
BR (2) BRPI0408767B8 (pt)
CA (1) CA2518437C (pt)
CL (1) CL2004000590A1 (pt)
CO (1) CO5601029A2 (pt)
ES (1) ES2574580T3 (pt)
HR (1) HRP20050830A2 (pt)
IL (1) IL170343A (pt)
MX (1) MXPA05010210A (pt)
NO (1) NO334095B1 (pt)
NZ (1) NZ541829A (pt)
RU (1) RU2342367C2 (pt)
TW (1) TW200505441A (pt)
WO (1) WO2004085411A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2375358C2 (ru) * 2004-04-01 2009-12-10 Авентис Фармасьютикалз, Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение
CA2574308C (en) * 2004-07-27 2014-03-25 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
CN101180280A (zh) * 2005-03-24 2008-05-14 弗·哈夫曼-拉罗切有限公司 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
DE602006004473D1 (de) * 2005-09-30 2009-02-05 Hoffmann La Roche Nnrt-inhibitoren
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
AR061838A1 (es) 2006-07-07 2008-09-24 Gilead Sciences Inc Moduladores de propiedades farmacocineticas de terapeuticos
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
KR101401811B1 (ko) 2006-08-16 2014-05-29 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 저해제
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP2118082B1 (en) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
KR20100015435A (ko) * 2007-04-09 2010-02-12 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사효소 저해제
WO2008145563A2 (en) * 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Process for preparing triazolones
AU2008257771B2 (en) 2007-05-30 2015-02-19 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
WO2008157330A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
KR20100039348A (ko) * 2007-06-22 2010-04-15 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역 전사효소 억제제로서 우레아 및 카바메이트 유도체
US8492415B2 (en) * 2007-07-03 2013-07-23 Yale University Azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) in antiviral therapy (HIV)
CN101903382B (zh) * 2007-12-21 2012-11-28 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
HUE025336T2 (en) * 2010-03-30 2016-03-29 Merck Canada Inc Non-nucleoside reverse transcriptase inhibitors
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
CN104230929B (zh) * 2013-06-19 2015-11-18 华东师范大学 一种非核苷类hiv-1反转录酶抑制剂
LT3125894T (lt) 2014-04-01 2020-12-10 Merck Sharp & Dohme Corp. Živ atvirkštinės transkriptazės inhibitorių provaistai

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) * 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4942236A (en) * 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US4966909A (en) 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
JP2002275165A (ja) * 2001-01-12 2002-09-25 Sumitomo Pharmaceut Co Ltd トリアゾール誘導体

Also Published As

Publication number Publication date
US7348345B2 (en) 2008-03-25
KR101122456B1 (ko) 2012-04-26
NO20054264L (no) 2005-10-14
BRPI0408767B1 (pt) 2017-10-31
US20070179157A1 (en) 2007-08-02
RU2005132632A (ru) 2006-06-10
TW200505441A (en) 2005-02-16
NO334095B1 (no) 2013-12-09
BR122016023941B1 (pt) 2021-10-13
AR043673A1 (es) 2005-08-03
EP1608633B1 (en) 2016-04-20
JP2006521319A (ja) 2006-09-21
KR20050115294A (ko) 2005-12-07
IL170343A (en) 2014-03-31
HRP20050830A2 (en) 2006-09-30
CO5601029A2 (es) 2006-01-31
CN1759104A (zh) 2006-04-12
CA2518437A1 (en) 2004-10-07
AU2004224153A1 (en) 2004-10-07
BRPI0408767B8 (pt) 2021-05-25
CN100588650C (zh) 2010-02-10
EP1608633A1 (en) 2005-12-28
NZ541829A (en) 2008-11-28
US7208509B2 (en) 2007-04-24
ES2574580T3 (es) 2016-06-20
JP4708329B2 (ja) 2011-06-22
AU2004224153B2 (en) 2009-04-02
CA2518437C (en) 2012-07-10
CL2004000590A1 (es) 2005-02-04
RU2342367C2 (ru) 2008-12-27
NO20054264D0 (no) 2005-09-15
MXPA05010210A (es) 2005-11-23
US20040192704A1 (en) 2004-09-30
WO2004085411A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0408704A (pt) benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0208811B8 (pt) derivados de pirazol, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BRPI0610030B8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0516972A (pt) composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
BR0213967A (pt) Análogos de himbacina como antagonistas do receptor de trombina
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
SE0402735D0 (sv) Novel compounds
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR0212069A (pt) Agentes antidiabéticos orais
BR0315801A (pt) Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.